**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 65449

**Manuscript Type:** REVIEW

**Nonalcoholic fatty pancreas disease: An emerging clinical challenge**

Zhang CL *et al*. Emerging clinical challenge of NAFPD

Cheng-Lei Zhang, Jing-Jiao Wang, Jian-Ning Li, Yi Yang

**Cheng-Lei Zhang,** Department of Clinical Laboratory, General Hospital of Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China

**Cheng-Lei Zhang, Jian-Ning Li, Yi Yang,** The Institute of Endocrinology, Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China

**Jing-Jiao Wang,** Department of Stomatology, General Hospital of Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China

**Jian-Ning Li, Yi Yang,** School of Basic Medical Sciences, Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China

**Author contributions:** Zhang CL, Wang JJ, Li JN, and Yang Y designed the research study; all authors have read and approved the final manuscript.

**Corresponding author: Yi Yang, PhD, Professor,** School of Basic Medical Sciences, Ningxia Medical University, No. 692 Shengli Street, Xingqing District, Yinchuan 750004, Ningxia Hui Autonomous Region, China. yangyi0908666@163.com

**Received:** March 11, 2021

**Revised:** May 20, 2021

**Accepted:** June 1, 2021

**Published online:**

**Abstract**

Nonalcoholic fatty pancreas disease (NAFPD) is an emerging disease that has gained an increasing amount of attention in recent years. It describes fat accumulation in the pancreas with insignificant alcohol consumption, but the pathogenesis is largely unknown. A wide range of terms have been used to describe the phenomenon of pancreatic fat accumulation, but NAFPD remains an under-recognized and non-independent disorder. Obesity, age, sex, race, and unhealthy lifestyle are established independent risk factors for NAFPD, which is strongly associated with metabolic syndrome, type 2 diabetes, pancreatitis, pancreatic fistula, pancreatic cancer, and nonalcoholic fatty liver disease. At present, imaging techniques are common diagnostic aids, but uniform criteria and consensus are lacking. Therapeutically, healthy diet, weight loss, and exercise are the mainstays to reduce pancreatic fat accumulation. It can be seen that there is a limited understanding of NAFPD at this stage and further exploration is needed. Previous studies have revealed that NAFPD may directly affect diagnosis and clinical decision-making. Therefore, exploring the pathophysiological mechanism and clinical associations of NAFPD is a major challenge for researchers and clinicians.

**Key Words:** Nonalcoholic fatty pancreatic disease; Pancreatic steatosis; Obesity; Metabolic syndrome; Pancreatic disease; Pancreas

Zhang CL, Wang JJ, Li JN, Yang Y. Nonalcoholic fatty pancreas disease: An emerging clinical challenge. *World J Clin Cases* 2021; In press

**Core Tip:** Just as obesity is a global problem, nonalcoholic fatty pancreas disease (NAFPD) has attracted an increasing amount of attention from researchers and clinicians. In this review, we have summarized the recent progress of NAFPD, including risk factors, pathogenesis, diagnosis, and clinical consequences. The value of NAFPD as early indication of diagnosis and intervention in patients with metabolic syndrome, type 2 diabetes, and pancreatitis is important. In the future, it is reasonably expected that large cohort and multi-center basic and clinical research can deepen our knowledge of NAFPD, so that the early diagnosis and treatment of NAFPD and clinical associations can be made possible.

**INTRODUCTION**

Obesity has become the most important global health problem, with the proportion of obese people increasing at an unprecedented rate. Overweight in adults is defined by the World Health Organization as body mass index (BMI) ≥ 25 kg/m2, and obesity as BMI ≥ 30 kg/m2. As of 2016, > 1.9 billion adults were overweight, > 650 million were obese, and at least 2.8 million deaths were occurring yearly from overweight or obesity. Multiple comorbidities associated with obesity result in a global health burden and exhibit a variety of disorders, including metabolic syndrome (MetS), cardio/cerebrovascular diseases, psychiatric disease, and malignancy[1,2]. Recently, studies have focused on ectopic fat deposition in organs induced by obesity, known as steatosis[3,4]. Large studies have investigated hepatic fatty infiltration, which contributes to the 30% prevalence of nonalcoholic fatty liver disease (NAFLD)[5,6]. Continuous progression of NAFLD may lead to nonalcoholic steatohepatitis (NASH), cirrhosis, and liver cancer. Although NAFLD has been extensively researched and its relationship with metabolic disorders has been determined, ectopic fat accumulation in the pancreas and its clinical significance have received little attention until recently.

Correlation between pancreatic weight and total body weight was first described by Schaefer in 1926[7]. The concept of pancreatic steatosis was first described in 1933 when Ogilvie[8] observed that the quantity of pancreatic fat was double in obese individuals compared with that in nonobese individuals. Years later, Olsen[9] found an increased amount of pancreatic fat in a direct relationship to age after an autopsy study of 394 cases. Subsequently, Stamm[10] reached the same conclusion and found a significant relationship between pancreatic steatosis and the risk of type 2 diabetes mellitus (T2DM) and atherosclerosis when the pancreatic fat content was > 25%. Several synonyms have been used for pancreatic fat accumulation (Table 1) (adjusted according to Smits and van Geenen[11] and Tariq *et al*[12]). Nonalcoholic fatty pancreas disease (NAFPD) is defined as pancreatic fat accumulation associated with obesity and absence of significant alcohol consumption[11]. Significant alcohol consumption is considered to be > 20 g/d.

Epidemiological data are not numerous due to the lack of standardized tests. The prevalence of NAFPD ranges from 16% to 35% in Asians[13]. A study of 4419 Chinese adults found a prevalence of NAFPD of 11% and a higher incidence with age and a gender difference in adults < 55 years[14]. A meta-analysis, pooling data on NAFPD from 11 studies (12675 individuals), yielded a prevalence of 33% (95% confidence interval, 24%-41%)[15]. Although epidemiological data are scarce, such a high prevalence cannot be ignored. A cross-sectional study from Medistra Hospital, Jakarta showed that NAFPD had significant associations with metabolic factors such as fasting plasma glucose, triglyceride (TG), and cholesterol levels, which might play an important role in the risk of malignancy[16]. NAFPD is strongly associated with metabolic risk factors as a significant manifestation of MetS and obesity[17]. Currently, with the development and application of advanced diagnostic techniques, clinical data on NAFPD will be widely acquired and receive more attention.

**RISK FACTORS AND PATHOGENESIS**

To this day, several risk factors of NAFPD have been identified, with obesity being widely accepted as the most important[18]. Under the condition of obesity, two mechanisms contribute to pancreatic fat accumulation. The first is called fat replacement, in which dead acinar cells are substituted by adipocytes. The second is called fat infiltration, which refers to fat accumulation[11]. Experimental studies in mice have shown that maternal obesogenic diets during pregnancy and lactation induce alterations in endoplasmic reticulum stress, such as the unfolded protein response, and also lead to alterations in circadian metabolic patterns through biological clock-molecular core circadian genes, resulting in NAFPD[19,20].

In addition to obesity, age is another significant risk factor. Epidemiological studies have shown a positive association between age and NAFPD[14,21], and men may have a higher risk of NAFPD[22]. This does not mean, however, that the risk of NAFPD in children can be overlooked[23]. As a major associated disease, NAFLD has been implicated as a significant risk factor leading to NAFPD. A study of 293 patients with NAFPD found a 67.9% concurrence rate with NAFLD and a negative predictive value for NAFLD of 96.4% with a normal pancreas[22]. Multiple regression analysis concluded that NAFLD is the strongest predictor for NAFPD[24]. There appears to be a link between NAFPD and NASH, with 50% of NASH patients suffering from NAFPD[25]. A previous study indicates that NAFPD is significantly associated with advanced fibrosis but not NASH. The authors stated that NAFPD is a safe, inexpensive index to rule out advanced fibrosis as the negative predictive value of NAFPD for advanced fibrosis is 93%[26]. In addition to this, hypertension, lower serum lipase activity, hyperferritinemia, and lifestyle factors (*e.g.*, sedentary, smoking, and frequent meat consumption) might be relevant for NAFPD[24,27-31].

With regard to NAFPD pathogenesis, some evidence indicates that NAFPD may be associated with adipocyte-derived inflammatory factors, especially those induced by free fatty acids (FFAs). The expression of interleukin (IL)-6, tumor necrosis factor (TNF)-α, and monocyte chemoattractant protein-1 increase in rats with FFA-induced hyperlipidemia, and the levels of body and epididymal fat increased significantly[32,33]. Treatment of SZ95 sebocytes with palmitic acid, a major saturated FFA, resulted in a significant increase in intracellular fat levels and upregulated expression of IL-6 and IL-8 messenger RNA, as well as secretion of these inflammatory cytokines[34]. Similarly, palmitic acid induces monocyte chemoattractant protein-1 secretion and monocyte infiltration in renal tubular epithelial cells, which aggravates the inflammatory response[35]. However, not all FFAs have the same effect, which may be due to the differences in unsaturated double bonds and spatial conformation. A recent study has shown that saturated fatty acids (palmitic acid) and polyunsaturated fatty acids (γ-linolenic acid and arachidonic acid) have minor effects on the gene expression of inflammatory factors (IL-6, TNF-α, and cyclooxygenase-2) in peripheral blood mononuclear cells, while monounsaturated fatty acids (oleic acid), polyunsaturated fatty acids (α-linolenic acid), and docosahexaenoic acid decreased the gene expression of inflammation[36]. In addition, pancreatic fat accumulation and inflammatory response are aggravated in splenectomy-treated obese mice, which are inhibited by targeted administration of anti-inflammatory cytokine IL-10[37]. Overexpression of serine/threonine protein kinase 25 in transgenic mice exacerbates high-fat-diet-induced pancreatic fat accumulation and is accompanied by inflammatory cell infiltration, apoptosis, and a marked decrease in islet β/α-cell ratio[38]. Current research is focusing on epidemiology and clinical complications of NAFPD, but there is a lack of fundamental research literature on genetics and molecular mechanisms. This could be related to the lack of clear awareness, and more comprehensive and in-depth research is needed.

**DIAGNOSIS OF NAFPD**

Given pancreatic fat accumulation as the dominating feature of NAFPD, histological biopsy is the gold standard for diagnosis[39-42]. A meta-analysis of mean pancreatic fat content in healthy volunteers suggested that a cutoff point of 6.2% may be recommended to distinguish normal pancreatic tissue from pancreatic fat accumulation[15]. It is unclear whether the normal state is lower than 6.2%, and whether 6.2% can be considered as the threshold NAFPD associated diseases (such as NASH). More studies with larger sample sizes are needed to determine the rationality, and further prospective studies are required to validate the applicability of this threshold. More importantly, due to the complex anatomical location of the pancreas and invasive operation, histological biopsy is inadequate for routine clinical applications, likely conferring adverse outcome in patients. Additionally, the inhomogeneity of pancreatic fat accumulation has been suggested in imaging studies[43], causing challenges in sampling and analysis of histological biopsy.

Consequently, noninvasive diagnostic methods for NAFPD may be the optimal way for clinical application. Transabdominal ultrasonography (TUS) is a widely available method with low cost and risk. The pancreas can be partially visualized with TUS because of gas inside the gastrointestinal tract. At the same time, this is also a challenge in obese patients to exhibit an apparent pancreas[44]. Pancreatic fat accumulation appears hyperechoic as compared with liver or kidney accumulation, a reference point for diagnosis[45,46]. Some studies have established that echogenicity of retroperitoneal fat suggests a higher amount of pancreatic fat deposition, using a grading system[22,25,7]. However, another limitation is that pancreatic fibrosis may also appear hyperechoic, which does not necessarily indicate pancreatic fat accumulation[48-50].Until now, there is no generally accepted method for quantitative assessment of pancreatic echotexture[51]. Endoscopic ultrasonography (EUS), as an invasive method, provides better assessment of the pancreas and has other features, such as biopsy and elastography, overcoming the visual and anatomical barriers of TUS[52]. However, it would not be appropriate to diagnose pancreatic fat accumulation solely on EUS, and further investigations of clinical implications need to be highlighted.

Computed tomography (CT) is considered to be a preferred imaging technique for abdominal organs and has a wide variety of clinical applications. Hounsfield units (HUs) are used to measure the severity of pancreatic fat accumulation, showing low-density compared with the spleen[53]. CT without contrast is recommended because the pancreatic parenchyma absorbs the contrast medium and is suspected to be a solid lesion[54]. The threshold of pancreatic fat accumulation is proposed to be 36 HU[55], but it has not gained wide acceptance[22,55,56]. However, pancreatic fat accumulation is usually not evenly distributed, posing difficulty in distinguishing fat in adipocytes from parenchymal cells, and it may not be able to assess accurately pancreatic fat content[57]. A previous study has found that CT using fat/parenchyma ratio is a reliable method[58], but further clinical data are needed for verification.

Magnetic resonance imaging (MRI) is an imaging technique combining spatial, anatomical, and quantitative data. Its signal arises from water and fat molecules within different organs, producing small differences in the resonance frequencies, thereby allowing quantification. MRI has many advantages as a diagnostic method, given its noninvasiveness, safety, and high sensitivity, and is applicable in to children[59]. In this way, MRI is the preferred method for diagnosis of pancreatic fat accumulation[60,61]. Proton magnetic resonance spectroscopy (1H-MRS) is considered to be the gold standard for noninvasive quantitative assessment of pancreatic fat accumulation. It deduces the spectrum of proton signaling by MRS acquired using point-resolved spectra or stimulated echo acquisition mode sequencing, and its diagnostic accuracy is comparable with histology[62,63]. However, the smaller size of the pancreas and inaccurate positioning while breathing might lead to detection errors. MRI chemical-shift imaging acquires the imaging signals using the chemical shift between water and fat within different organisms, completing detection in a single breath hold and thereby reducing errors due to breathing[64-66]. In recent years, based on the reconstruction algorithm, a new technique called iterative decomposition of echo asymmetry of water and fat with least squares estimation (IDEAL) has been developed. IDEAL can be used for evaluation of pancreatic fat content with accuracy and less signal contamination. It has been validated in animal models and is expected to replace MRS as the gold standard for quantifying pancreatic fat accumulation[59,67]. MRI proton density fat fraction (MRI-PDFF) is one of the state-of-the-art techniques, which addresses limitations of multipoint Dixon quantification and allows accurate quantification of pancreatic fat accumulation[68]. A previous study has suggested a diagnostic cutoff value for NAFPD of 10.4% using MRI-PDFF[29]. Currently, this approach has been applied not only to the pancreas but also to adjacent parenchymal organs in quantitating fat content[68].

Magnetic resonance elastography (MRE) can provide a quantitative assessment of the elasticity and structure of tissues by collecting dynamic propagation signals of vibration waves. MRE is now used for evaluating fibrosis, inflammation, and edema of tissues. This is the most accurate method for assessing hepatic fibrosis and correlates well with histological staging of fibrosis[69-71]. As mentioned earlier, the anatomical location and size of the pancreas can create challenges for the operator. MRE might be used as a noninvasive tool for detecting pancreatic fat accumulation, enhancing the ability to distinguish between pancreatic and retroperitoneal fat[72]. In previous MRE studies, the better credibility and repeatability of investigating pancreatic tissue have been identified[72]. However, there has been no relevant study on MRE evaluation of pancreatic fat accumulation. As mentioned above, it would not be appropriate to diagnose pancreatic fat accumulation solely by EUS. To complement EUS, elastography *via* EUS has been developed to evaluate pancreatic tumors and lymph nodes that are hard to reach. This adds dynamic quantification of elasticity of the target tissue, differentiates benign and malignant tissue, and predicts the exocrine dysfunction of chronic pancreatitis[69]. Clinical practice guidelines for pancreatic elastography have been published[73]. The high precision of pancreatic elastography will improve with continued technological advancement.

Although the imaging techniques mentioned above can be used to evaluate pancreatic fat accumulation, the limited research has limited their clinical use[74]. Moreover, further studies on the indications, sensitivity, specificity, and cut-off values of these imaging techniques are awaited. The latest developed technique of organ segmentation is promising for evaluating the distribution of interlobular and intralobular septal pancreatic fat[75]. However, whole-organ segmentation and automatic analysis have greater trouble in technology.

**CLINICAL CONSEQUENCES OF NAFPD**

***MetS***

Unhealthy lifestyle and eating habits lead to the increasing prevalence of MetS. MetS is a group of complex metabolic perturbations, consisting of abdominal obesity, insulin resistance, hypertension, hypertriglyceridemia, and low plasma high-density lipoprotein–cholesterol levels; three of which must be fulfilled for diagnosis of MetS[76]. The risk of diabetes and cardiovascular disease are at high levels in individuals with MetS, which is closely correlated with progression of NAFLD. In recent years, several reports have revealed that a correlation exists between NAFPD and MetS and suggest that it must be part of the defini­tion of MetS[77-79]. Altered metabolism of fatty acids, induced by abdominal obesity, is a risk factor for cardiovascular disease and gastrointestinal disorders, including of the pancreas[80,81]. Whether the association of NAFPD and MetS is directly causal, or is a result of obesity, remains unclear and awaits further investigation.

***Endocrine dysfunction***

Obesity is a widely accepted significant risk factor for T2DM[82]. The fact that obesity has become a top global health problem may also explain, to some extent, the increasing incidence of T2DM[83]. NAFPD lies at the junction of obesity and T2DM. Endocrine dysfunction induced by NAFPD, including β-cell dysfunction and insulin resistance, is directly responsible for the development of T2DM. Insulin resistance due to pancreatic beta cell dysfunction contributes to the development of T2DM, which is thought to be the driving force behind the alarming prevalence of T2DM[21,84].

Animal experiments have shown that high-fat diet is a risk factor for pancreatic fat accumulation and β-cell apoptosis[85]. Long-term high-fat diet induces MetS in mice and eventually leads to insulin resistance, NAFPD and NAFLD[79]. Therefore, the correlation between NAFPD and β-cell dysfunction has been validated in animal models. The role of glucotoxicity and lipotoxicity is widely accepted in the pathogenesis of β-cell dysfunction[86]. Glycotoxicity induced by hyperglycemia hinders the process of mitochondrial β-oxidation and results in the accumulation of TGs in β-cells[87]. Likewise, the significant increase of FFA in the pancreas due to high-fat diet triggers pancreatic lipotoxicity, which leads to damage of pancreatic acinar and islet cells by inflammatory reaction[88].

Similarly, NAFPD is strongly associated with T2DM in humans. The pancreatic fat content of T2DM patients is significantly higher than that of patients without T2DM (measured by MRS)[89,90]. In contrast, the proportion of T2DM is significantly higher for NAFPD patients, comparing with control group[27]. NAFPD is independently related to prediabetes and diabetes in men[21], and the pancreatic fat content is negatively associated with insulin secretion in prediabetes[62]. A cross-sectional study enrolling 8097 subjects not only found a higher prevalence of NAFPD in the general population but also revealed an association between NAFPD and T2DM[27]. NAFPD may be another independent risk factor for the development of T2DM in addition to NAFLD[21]. To date, only one 7-year longitudinal population-based retrospective cohort study has investigated the association between NAFPD and the incidence of T2DM. NAFPD was positively associated with increased T2DM incidence. However, after adjustment for confounders, including BMI and liver attenuation, this association disappeared. Therefore, further studies with a longer follow-up period as well as studies in other ethnic groups are needed to confirm these findings[91]. In addition, there appears to be an ethnic predilection for the phenomenon of crosstalk between glucose and FFA. This predilection is reflected in obese Hispanics, who have higher pancreatic TG levels compared with African Americans and a greater decline of β-cell function compared with Caucasians with similar pancreatic TG levels[92]. The mechanism of this ethnic predilection remains unclear, and further studies are needed to determine how this occurs.

The association between NAFPD and insulin resistance is still controversial. Using the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) and euglycemic clamp to measure insulin resistance, the positive correlation between insulin resistance and the severity of NAFPD was observed in patients with impaired fasting glucose and/or impaired glucose tolerance[22,93]. Other investigations have also found an association between NAFPD and markers of insulin resistance[94,95]. However, it remains controversial whether this association is independent of obesity and NAFLD. A previous study has found higher levels of insulin resistance, IL-1 β, and TNF-α in obese children with NAFLD but lower levels in children with NAFPD[96]. In a multivariate logistic regression analysis, the association between NAFPD and HOMA-IR disappeared after further adjustment for visceral fat, rather than overall adiposity or pancreatic fat, suggesting that the former mediates the association between NAFPD and insulin resistance[22]. Consequently, the real issue is whether NAFPD really is the cause of insulin resistance, or if it is only a part of the abnormalities in the process of obesity.

***Exocrine dysfunction***

Exocrine pancreatic dysfunction is a deficiency of enzyme secretion due to several pathological factors and can be secondary to pancreatectomy or pancreatic diseases, especially chronic pancreatitis. NAFPD may also be a potential factor in exocrine dysfunction[53,97]. Several studies have pointed to the fact that NAFPD is the second leading cause of pediatric pancreatic insufficiency and coexists with exocrine dysfunction, which is frequently present in a few childhood syndromes such as Johanson-Blizzard syndrome and Schwachman-Diamond syndrome[98]. To date, there have been few reports regarding NAFPD and exocrine dysfunction[99-102]. A recent study enrolling 43 patients with NAFPD found a significant reduction of fecal elastase-1, a widely utilized indicator of pancreatic exocrine function, in patients with NAFPD in comparison to those patients without NAFPD[103]. Patients with endocrine dysfunction develop symptoms of malabsorption such as steatorrhea, bloating, abdominal pain, and weight loss, while complete fatty replacement is seen on imaging studies[101,104,105]. In addition, NAFPD has been also confirmed as a major cause of chronic pancreatitis and ductal stones[106]. The oxidative stress resulting from NAFPD could lead to exocrine dysfunction. Furthermore, adipocytes probably enact a paracrine effect, decreasing pancreatic exocrine function[40,41,107]. Nevertheless, these mechanisms have only been studied *in vitro* and require *in vivo* studies for confirmation.

***Acute pancreatitis***

As a major risk factor for severe acute pancreatitis, obesity is closely associated with multiple organ failure[108-110]. Obese mice develop more severe pancreatitis after hyperstimulation of pathogenic factors than lean mice do[111]. In addition, NAFPD is associated with organ failure[112], local complications[113], prolonged hospitalization[114], and increased mortality in patients with pancreatitis[109,115].

Mechanistic hypotheses regarding the causal relationship between obesity and acute pancreatitis have been previously presented, including that pancreatic microcirculation in NAFPD patients is reduced, with a consequent reduction in local oxygen content and ischemic injury. The second is that hepatic dysfunction associated with obesity might enhance the systemic inflammation, and local inflammation due to NAFPD is usually located in the pancreatic fat[116]. Adipocytes can secret chemokines and cytokines, an imbalance of which causes a developing inflammatory state[117,118]. The cytokines (IL-1β and TNF-α) produced by adipocytes in combination with free radicals derived from fatty acids create a proinflammatory milieu that leads to acinar cell injury and exacerbates the severity of acute pancreatitis[96,110,119]. Analogous to the association of NAFLD and NASH, the condition of pancreatitis owing to NAFPD has been termed nonalcoholic steatopancreatitis[78,120,121].

***Pancreatic fistula***

Pancreatic fistula is a potentially life-threatening complication after pancreatoduodenectomy[122]. Mathur *et al*[42] were the first to report that NAFPD significantly increased the risk of developing postoperative pancreatic fistula (POPF). Subsequently, the relevance of NAFPD to POPF has been confirmed[123-126]. It has been shown that pancreatic fat content > 10% is a significant risk factor for POPF[127], while the prognosis of patients is significantly associated with pancreatic fat content[53]. Currently, preoperative evaluation of risk factors has been considered to be a viable approach in preventing POPF. The high incidence of NAFPD in patients with POPF detected by preoperative CT has led to the proposal that preoperative assessment of NAFPD by CT could be used as a noninvasive method to predict POPF[128]. Guo *et al*[129] retrospectively evaluated the relative weights of several factors, including NAFPD, and established a simplified scoring model for precise prediction of POPF. Next, multicenter prospective studies, as well as improvement in the accuracy of scoring model, should be performed with a view to application in the preoperative assessment of pancreatoduodenectomy.

***Pancreatic cancer***

With obesity becoming the top global health problem, there is increasing evidence that obesity is a risk factor for pancreatic cancer[130-133]. Whereas obesity is strongly associated with NAFPD, similar to NAFLD, it is thought that NAFPD may drive the progression of pancreatic cancer by nonalcoholic steatopancreatitis or fibrosis[134]. Several findings support this view, but evidence is still limited. A retrospective study has reported a prevalence of NAFPD in patients with pancreatic cancer by EUS, which is the most sensitive for NAFPD. Compared with other risk factors, NAFPD is the only significant risk factor for pancreatic cancer in regression analysis[135]. There is a direct association between NAFPD and the incidence of intraepithelial neoplasia and pancreatic ductal adenocarcinoma, as shown by histopathology[136,137]. Currently, NAFPD is independently associated with the risk of pancreatic cancer[136]. In addition, NAFPD promotes the dissemination of pancreatic cancer[138] and significantly increases the risk of postoperative complications[139] and mortality[140].

Nevertheless, no clear consensus can be reached on the definitive mechanism for pancreatic cancer linked to NAFPD. MetS, oxidative stress, adipocytokine imbalance, and inflammation may contribute to the development of pancreatic cancer[141]. Abnormally increased adipocytes in the setting of NAFPD result in an adipocytokine imbalance, creating a proinflammatory milieu that aggravates the risk of recurrent pancreatitis, which is considered a major risk factor for pancreatic cancer. More fundamental mechanistic studies as well as prospective cohort studies with long-term follow-up are needed to clarify the causal link between NAFPD and pancreatic cancer.

***NAFLD***

The pancreas and liver are from the same embryonic endoderm, which may explain to some extent the similarities and links of fat accumulation in both NAFPD and NAFLD[142]. However, the pancreas seems to be more susceptible to fat accumulation compared with the liver[41]. Data from TUS, MRS, and histopathology have demonstrated a significant positive correlation between NAFPD and NAFLD[15,22,61], with NAFPD present in nearly 70% of patients with NAFLD and associated with its well-known risk factors including MetS, T2DM, and obesity[27,143,144]. NAFPD is comorbid in approximately half of pediatric patients with NAFLD, corresponding to a combined NAFPD in 80% of NASH patients, and NAFLD children with NAFPD have more severe insulin resistance and liver disease[96]. Although both NAFPD and NAFLD are associated with obesity, pancreatic fat accumulation might be the initial indicator of ectopic fat accumulation, as a strong determinant of NAFLD and MetS[27].

**TREATMENT**

Given the similarities with NAFLD, early treatment of NAFPD should be emphasized with the goal of minimizing pancreatic fat accumulation through healthy dieting, weight loss, and exercise[145]. Lifestyle modifications such as reducing caloric intake and meat consumption may benefit patients with NAFPD[146,147]. However, Weng *et al*[14] found a nonsignificant trend between NAFPD and sedentary habits as well as smoking.

Evidence for the reversibility of NAFPD has been found in animal and human studies. Troglitazone and orlistat administered to mouse models significantly prevent or reverse pancreatic inflammation and fat infiltration and reduce organ failure and mortality[148,149]. Liraglutide, a drug approved for obesity, has been shown to reduce the severity of NAFPD and NAFLD, while metformin has no significant effect on NAFPD[150,151]. Combination of sitagliptin and telmisartan demonstrates efficacy in controlling NAFPD progression[152]. In addition, berberine and cinnamic acid (traditional Chinese medicines) show prevention of NAFPD development by inhibiting fat accumulation[153]. Besides drug therapy, the impact of weight loss on NAFPD after bariatric surgery has been studied in animal and human models. Bariatric surgery in NAFPD patients has the benefits of decreasing pancreatic fat volume and improving β-cell function[89,127]. Of note, the degree of reduction in pancreatic fat content does not correlate with reduction in total body weight, suggesting differences in metabolic phenotype[15].

**CONCLUSION**

Just as obesity is a global problem, NAFPD has attracted a great deal of attention from researchers and clinicians. Understanding of NAFPD is still in its infancy since its discovery for its relation to obesity. Age, gender, race, and unhealthy lifestyle are considered as risk factors. A variety of invasive and noninvasive tools have been developed for diagnosis including 1H-MRS, IDEAL-MRI, MRI-PDFF, and EUS elastography; some of which have reached consensus guidelines. Improvement of diagnostic tools help us to understand better changes involved in NAFPD pathophysiology and the microscopic pathophysiological relationship between NAFPD and other pancreatic diseases, so as to provide the groundwork for novel therapies for NAFPD.

Because of the close correlation, NAFPD should be considered in clinical practice for related diseases, including MetS, T2DM, pancreatitis, POPF, pancreatic cancer, and NAFLD. The value of NAFPD as an early indication of diagnosis and intervention in patients with MetS, T2DM, and pancreatitis and as a prognostic marker for pancreatic surgery and postoperative complications is important. Nowadays, lifestyle modifications, including structured exercise and prudent diet, remain the cornerstones of NAFPD treatment. In the future, it is reasonably expected that systematic basic and clinical research will elucidate the pathogenesis, influencing factors, and clinical complications of NAFPD. Large cohort, multicenter investigations should be performed to deepen our knowledge of NAFPD, so that the early diagnosis and treatment of NAFPD and clinical associations can be made possible.

**REFERENCES**

1 **Passarello K**, Kurian S, Villanueva V. Endometrial Cancer: An Overview of Pathophysiology, Management, and Care. *Semin Oncol Nurs* 2019; **35**: 157-165 [PMID: 30867105 DOI: 10.1016/j.soncn.2019.02.002]

2 **Saboor Aftab SA**, Kumar S, Barber TM. The role of obesity and type 2 diabetes mellitus in the development of male obesity-associated secondary hypogonadism. *Clin Endocrinol (Oxf)* 2013; **78**: 330-337 [PMID: 23121123 DOI: 10.1111/cen.12092]

3 **Bobulescu IA**, Lotan Y, Zhang J, Rosenthal TR, Rogers JT, Adams-Huet B, Sakhaee K, Moe OW. Triglycerides in the human kidney cortex: relationship with body size. *PLoS One* 2014; **9**: e101285 [PMID: 25170827 DOI: 10.1371/journal.pone.0101285]

4 **Feldman M**, Friedman LS, Sleisenger MH, Scharschmidt BF. Sleisenger and Fordtran's gastrointestinal and liver disease: pathophysiology, diagnosis, management electronic resource. Elsevier, 2016

5 **Le MH**, Devaki P, Ha NB, Jun DW, Te HS, Cheung RC, Nguyen MH. Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. *PLoS One* 2017; **12**: e0173499 [PMID: 28346543 DOI: 10.1371/journal.pone.0173499]

6 **Hales CM**, Carroll MD, Fryar CD, Ogden CL. Prevalence of Obesity Among Adults and Youth: United States, 2015-2016. *NCHS Data Brief* 2017: 1-8 [PMID: 29155689]

7 **Schaefer JH**. The normal weight of the pancreas in the adult human being: A biometric study. *Anatomic Record* 1926; **32**: 119-132

8 **Ogilvie RF**. The islands of langerhans in 19 cases of obesity. *J Pathol Bacteriol* 1933; **37**: 473-481

9 **Olsen TS**. Lipomatosis of the pancreas in autopsy material and its relation to age and overweight. *Acta Pathol Microbiol Scand A* 1978; **86A**: 367-373 [PMID: 716899 DOI: 10.1111/j.1699-0463.1978.tb02058.x]

10 **Stamm BH**. Incidence and diagnostic significance of minor pathologic changes in the adult pancreas at autopsy: a systematic study of 112 autopsies in patients without known pancreatic disease. *Hum Pathol* 1984; **15**: 677-683 [PMID: 6745910 DOI: 10.1016/s0046-8177(84)80294-4]

11 **Smits MM**, van Geenen EJ. The clinical significance of pancreatic steatosis. *Nat Rev Gastroenterol Hepatol* 2011; **8**: 169-177 [PMID: 21304475 DOI: 10.1038/nrgastro.2011.4]

12 **Tariq H**, Nayudu S, Akella S, Glandt M, Chilimuri S. Non-Alcoholic Fatty Pancreatic Disease: A Review of Literature. *Gastroenterology Res* 2016; **9**: 87-91 [PMID: 28058076 DOI: 10.14740/gr731w]

13 **Yu TY**, Wang CY. Impact of non-alcoholic fatty pancreas disease on glucose metabolism. *J Diabetes Investig* 2017; **8**: 735-747 [PMID: 28371475 DOI: 10.1111/jdi.12665]

14 **Weng S**, Zhou J, Chen X, Sun Y, Mao Z, Chai K. Prevalence and factors associated with nonalcoholic fatty pancreas disease and its severity in China. *Medicine (Baltimore)* 2018; **97**: e11293 [PMID: 29953011 DOI: 10.1097/MD.0000000000011293]

15 **Singh RG**, Yoon HD, Wu LM, Lu J, Plank LD, Petrov MS. Ectopic fat accumulation in the pancreas and its clinical relevance: A systematic review, meta-analysis, and meta-regression. *Metabolism* 2017; **69**: 1-13 [PMID: 28285638 DOI: 10.1016/j.metabol.2016.12.012]

16 **Lesmana CR**, Pakasi LS, Inggriani S, Aidawati ML, Lesmana LA. Prevalence of Non-Alcoholic Fatty Pancreas Disease (NAFPD) and its risk factors among adult medical check-up patients in a private hospital: a large cross sectional study. *BMC Gastroenterol* 2015; **15**: 174 [PMID: 26652175 DOI: 10.1186/s12876-015-0404-1]

17 **Wu WC**, Wang CY. Association between non-alcoholic fatty pancreatic disease (NAFPD) and the metabolic syndrome: case-control retrospective study. *Cardiovasc Diabetol* 2013; **12**: 77 [PMID: 23688357 DOI: 10.1186/1475-2840-12-77]

18 **Pezzilli R**, Calculli L. Pancreatic steatosis: Is it related to either obesity or diabetes mellitus? *World J Diabetes* 2014; **5**: 415-419 [PMID: 25126389 DOI: 10.4239/wjd.v5.i4.415]

19 **Carter R**, Mouralidarane A, Soeda J, Ray S, Pombo J, Saraswati R, Novelli M, Fusai G, Rappa F, Saracino C, Pazienza V, Poston L, Taylor PD, Vinciguerra M, Oben JA. Non-alcoholic fatty pancreas disease pathogenesis: a role for developmental programming and altered circadian rhythms. *PLoS One* 2014; **9**: e89505 [PMID: 24657938 DOI: 10.1371/journal.pone.0089505]

20 **Soeda J**, Mouralidarane A, Cordero P, Li J, Nguyen V, Carter R, Kapur SR, Pombo J, Poston L, Taylor PD, Vinciguerra M, Oben JA. Maternal obesity alters endoplasmic reticulum homeostasis in offspring pancreas. *J Physiol Biochem* 2016; **72**: 281-291 [PMID: 26979740 DOI: 10.1007/s13105-016-0476-6]

21 **Ou HY**, Wang CY, Yang YC, Chen MF, Chang CJ. The association between nonalcoholic fatty pancreas disease and diabetes. *PLoS One* 2013; **8**: e62561 [PMID: 23671610 DOI: 10.1371/journal.pone.0062561]

22 **Lee JS**, Kim SH, Jun DW, Han JH, Jang EC, Park JY, Son BK, Kim SH, Jo YJ, Park YS, Kim YS. Clinical implications of fatty pancreas: correlations between fatty pancreas and metabolic syndrome. *World J Gastroenterol* 2009; **15**: 1869-1875 [PMID: 19370785 DOI: 10.3748/wjg.15.1869]

23 **Pham YH**, Bingham BA, Bell CS, Greenfield SA, John SD, Robinson LH, Eissa MA. Prevalence of Pancreatic Steatosis at a Pediatric Tertiary Care Center. *South Med J* 2016; **109**: 196-198 [PMID: 26954660 DOI: 10.14423/SMJ.0000000000000432]

24 **Al-Haddad M**, Khashab M, Zyromski N, Pungpapong S, Wallace MB, Scolapio J, Woodward T, Noh K, Raimondo M. Risk factors for hyperechogenic pancreas on endoscopic ultrasound: a case-control study. *Pancreas* 2009; **38**: 672-675 [PMID: 19506531 DOI: 10.1097/MPA.0b013e3181a9d5af]

25 **Uygun A**, Kadayifci A, Demirci H, Saglam M, Sakin YS, Ozturk K, Polat Z, Karslioglu Y, Bolu E. The effect of fatty pancreas on serum glucose parameters in patients with nonalcoholic steatohepatitis. *Eur J Intern Med* 2015; **26**: 37-41 [PMID: 25491010 DOI: 10.1016/j.ejim.2014.11.007]

26 **Rosenblatt R**, Mehta A, Snell D, Hissong E, Kierans AS, Kumar S. Ultrasonographic Nonalcoholic Fatty Pancreas Is Associated with Advanced Fibrosis in NAFLD: A Retrospective Analysis. *Dig Dis Sci* 2019; **64**: 262-268 [PMID: 30269271 DOI: 10.1007/s10620-018-5295-x]

27 **Wang CY**, Ou HY, Chen MF, Chang TC, Chang CJ. Enigmatic ectopic fat: prevalence of nonalcoholic fatty pancreas disease and its associated factors in a Chinese population. *J Am Heart Assoc* 2014; **3**: e000297 [PMID: 24572250 DOI: 10.1161/JAHA.113.000297]

28 **Kühn JP**, Berthold F, Mayerle J, Völzke H, Reeder SB, Rathmann W, Lerch MM, Hosten N, Hegenscheid K, Meffert PJ. Pancreatic Steatosis Demonstrated at MR Imaging in the General Population: Clinical Relevance. *Radiology* 2015; **276**: 129-136 [PMID: 25658037 DOI: 10.1148/radiol.15140446]

29 **Wong VW**, Wong GL, Yeung DK, Abrigo JM, Kong AP, Chan RS, Chim AM, Shen J, Ho CS, Woo J, Chu WC, Chan HL. Fatty pancreas, insulin resistance, and β-cell function: a population study using fat-water magnetic resonance imaging. *Am J Gastroenterol* 2014; **109**: 589-597 [PMID: 24492753 DOI: 10.1038/ajg.2014.1]

30 **Lingvay I**, Esser V, Legendre JL, Price AL, Wertz KM, Adams-Huet B, Zhang S, Unger RH, Szczepaniak LS. Noninvasive quantification of pancreatic fat in humans. *J Clin Endocrinol Metab* 2009; **94**: 4070-4076 [PMID: 19773401 DOI: 10.1210/jc.2009-0584]

31 **Sepe PS**, Ohri A, Sanaka S, Berzin TM, Sekhon S, Bennett G, Mehta G, Chuttani R, Kane R, Pleskow D, Sawhney MS. A prospective evaluation of fatty pancreas by using EUS. *Gastrointest Endosc* 2011; **73**: 987-993 [PMID: 21521567 DOI: 10.1016/j.gie.2011.01.015]

32 **Hong CP**, Yun CH, Lee GW, Park A, Kim YM, Jang MH. TLR9 regulates adipose tissue inflammation and obesity-related metabolic disorders. *Obesity (Silver Spring)* 2015; **23**: 2199-2206 [PMID: 26260403 DOI: 10.1002/oby.21215]

33 **Wang C**, Zhang M, Wu J, Li W, Ha X, Gu Y, Han B, Xie J, Zhang J. The Effect and Mechanism of TLR9/KLF4 in FFA-Induced Adipocyte Inflammation. *Mediators Inflamm* 2018; **2018**: 6313484 [PMID: 30662369 DOI: 10.1155/2018/6313484]

34 **Choi CW**, Kim Y, Kim JE, Seo EY, Zouboulis CC, Kang JS, Youn SW, Chung JH. Enhancement of lipid content and inflammatory cytokine secretion in SZ95 sebocytes by palmitic acid suggests a potential link between free fatty acids and acne aggravation. *Exp Dermatol* 2019; **28**: 207-210 [PMID: 30506807 DOI: 10.1111/exd.13855]

35 **Sun H**, Sun Z, Varghese Z, Guo Y, Moorhead JF, Unwin RJ, Ruan XZ. Nonesterified free fatty acids enhance the inflammatory response in renal tubules by inducing extracellular ATP release. *Am J Physiol Renal Physiol* 2020; **319**: F292-F303 [PMID: 32686520 DOI: 10.1152/ajprenal.00098.2020]

36 **Sureda A**, Martorell M, Bibiloni MDM, Bouzas C, Gallardo-Alfaro L, Mateos D, Capó X, Tur JA, Pons A. Effect of Free Fatty Acids on Inflammatory Gene Expression and Hydrogen Peroxide Production by Ex Vivo Blood Mononuclear Cells. *Nutrients* 2020; **12** [PMID: 31947975 DOI: 10.3390/nu12010146]

37 **Gotoh K**, Inoue M, Shiraishi K, Masaki T, Chiba S, Mitsutomi K, Shimasaki T, Ando H, Fujiwara K, Katsuragi I, Kakuma T, Seike M, Sakata T, Yoshimatsu H. Spleen-derived interleukin-10 downregulates the severity of high-fat diet-induced non-alcoholic fatty pancreas disease. *PLoS One* 2012; **7**: e53154 [PMID: 23285260 DOI: 10.1371/journal.pone.0053154]

38 **Nuñez-Durán E**, Chanclón B, Sütt S, Real J, Marschall HU, Wernstedt Asterholm I, Cansby E, Mahlapuu M. Protein kinase STK25 aggravates the severity of non-alcoholic fatty pancreas disease in mice. *J Endocrinol* 2017; **234**: 15-27 [PMID: 28442507 DOI: 10.1530/JOE-17-0018]

39 **López JM**, Bombi JA, Valderrama R, Giménez A, Parés A, Caballería J, Imperial S, Navarro S. Effects of prolonged ethanol intake and malnutrition on rat pancreas. *Gut* 1996; **38**: 285-292 [PMID: 8801213 DOI: 10.1136/gut.38.2.285]

40 **Lee Y**, Lingvay I, Szczepaniak LS, Ravazzola M, Orci L, Unger RH. Pancreatic steatosis: harbinger of type 2 diabetes in obese rodents. *Int J Obes (Lond)* 2010; **34**: 396-400 [PMID: 20010902 DOI: 10.1038/ijo.2009.245]

41 **Pinnick KE**, Collins SC, Londos C, Gauguier D, Clark A, Fielding BA. Pancreatic ectopic fat is characterized by adipocyte infiltration and altered lipid composition. *Obesity (Silver Spring)* 2008; **16**: 522-530 [PMID: 18239594 DOI: 10.1038/oby.2007.110]

42 **Mathur A**, Pitt HA, Marine M, Saxena R, Schmidt CM, Howard TJ, Nakeeb A, Zyromski NJ, Lillemoe KD. Fatty pancreas: a factor in postoperative pancreatic fistula. *Ann Surg* 2007; **246**: 1058-1064 [PMID: 18043111 DOI: 10.1097/SLA.0b013e31814a6906]

43 **Matsumoto S**, Mori H, Miyake H, Takaki H, Maeda T, Yamada Y, Oga M. Uneven fatty replacement of the pancreas: evaluation with CT. *Radiology* 1995; **194**: 453-458 [PMID: 7824726 DOI: 10.1148/radiology.194.2.7824726]

44 **Choi CW**, Kim GH, Kang DH, Kim HW, Kim DU, Heo J, Song GA, Park DY, Kim S. Associated factors for a hyperechogenic pancreas on endoscopic ultrasound. *World J Gastroenterol* 2010; **16**: 4329-4334 [PMID: 20818817 DOI: 10.3748/wjg.v16.i34.4329]

45 **Fujii M**, Ohno Y, Yamada M, Kamada Y, Miyoshi E. Impact of fatty pancreas and lifestyle on the development of subclinical chronic pancreatitis in healthy people undergoing a medical checkup. *Environ Health Prev Med* 2019; **24**: 10 [PMID: 30732577 DOI: 10.1186/s12199-019-0763-2]

46 **Hung CS**, Tseng PH, Tu CH, Chen CC, Liao WC, Lee YC, Chiu HM, Lin HJ, Yang WS, Chen MF, Wu MS. Increased Pancreatic Echogenicity with US: Relationship to Glycemic Progression and Incident Diabetes. *Radiology* 2018; **287**: 853-863 [PMID: 29613841 DOI: 10.1148/radiol.2018170331]

47 **Worthen NJ**, Beabeau D. Normal pancreatic echogenicity: relation to age and body fat. *AJR Am J Roentgenol* 1982; **139**: 1095-1098 [PMID: 6983252 DOI: 10.2214/ajr.139.6.1095]

48 **Schneider K**, Harms K, Fendel H. The increased echogenicity of the pancreas in infants and children: the white pancreas. *Eur J Pediatr* 1987; **146**: 508-511 [PMID: 3315685 DOI: 10.1007/BF00441605]

49 **Shawker TH**, Linzer M, Hubbard VS. Chronic pancreatitis: the diagnostic significance of pancreatic size and echo amplitude. *J Ultrasound Med* 1984; **3**: 267-272 [PMID: 6748140 DOI: 10.7863/jum.1984.3.6.267]

50 **Ustundag Y**, Ceylan G, Hekimoglu K. Pancreatic hyperechogenicity on endoscopic ultrasound examination. *World J Gastroenterol* 2011; **17**: 2061-2062 [PMID: 21528089 DOI: 10.3748/wjg.v17.i15.2061]

51 **Jeong HT**, Lee MS, Kim MJ. Quantitative analysis of pancreatic echogenicity on transabdominal sonography: correlations with metabolic syndrome. *J Clin Ultrasound* 2015; **43**: 98-108 [PMID: 25044163 DOI: 10.1002/jcu.22200]

52 **Khan NA**, Amin MS, Islam MZ. Pancreatic lipomatosis with massive steatorrhea. *Mymensingh Med J* 2011; **20**: 712-714 [PMID: 22081194]

53 **Catanzaro R**, Cuffari B, Italia A, Marotta F. Exploring the metabolic syndrome: Nonalcoholic fatty pancreas disease. *World J Gastroenterol* 2016; **22**: 7660-7675 [PMID: 27678349 DOI: 10.3748/wjg.v22.i34.7660]

54 **Kim HJ**, Byun JH, Park SH, Shin YM, Kim PN, Ha HK, Lee MG. Focal fatty replacement of the pancreas: usefulness of chemical shift MRI. *AJR Am J Roentgenol* 2007; **188**: 429-432 [PMID: 17242252 DOI: 10.2214/AJR.05.1095]

55 **Kim SY**, Kim H, Cho JY, Lim S, Cha K, Lee KH, Kim YH, Kim JH, Yoon YS, Han HS, Kang HS. Quantitative assessment of pancreatic fat by using unenhanced CT: pathologic correlation and clinical implications. *Radiology* 2014; **271**: 104-112 [PMID: 24475851 DOI: 10.1148/radiol.13122883]

56 **Katz DS**, Hines J, Math KR, Nardi PM, Mindelzun RE, Lane MJ. Using CT to reveal fat-containing abnormalities of the pancreas. *AJR Am J Roentgenol* 1999; **172**: 393-396 [PMID: 9930790 DOI: 10.2214/ajr.172.2.9930790]

57 **Lim S**, Bae JH, Chun EJ, Kim H, Kim SY, Kim KM, Choi SH, Park KS, Florez JC, Jang HC. Differences in pancreatic volume, fat content, and fat density measured by multidetector-row computed tomography according to the duration of diabetes. *Acta Diabetol* 2014; **51**: 739-748 [PMID: 24671510 DOI: 10.1007/s00592-014-0581-3]

58 **Saisho Y**, Butler AE, Meier JJ, Monchamp T, Allen-Auerbach M, Rizza RA, Butler PC. Pancreas volumes in humans from birth to age one hundred taking into account sex, obesity, and presence of type-2 diabetes. *Clin Anat* 2007; **20**: 933-942 [PMID: 17879305 DOI: 10.1002/ca.20543]

59 **Hu HH**, Kim HW, Nayak KS, Goran MI. Comparison of fat-water MRI and single-voxel MRS in the assessment of hepatic and pancreatic fat fractions in humans. *Obesity (Silver Spring)* 2010; **18**: 841-847 [PMID: 19834463 DOI: 10.1038/oby.2009.352]

60 **Gaborit B**, Abdesselam I, Kober F, Jacquier A, Ronsin O, Emungania O, Lesavre N, Alessi MC, Martin JC, Bernard M, Dutour A. Ectopic fat storage in the pancreas using 1H-MRS: importance of diabetic status and modulation with bariatric surgery-induced weight loss. *Int J Obes (Lond)* 2015; **39**: 480-487 [PMID: 25042860 DOI: 10.1038/ijo.2014.126]

61 **Hannukainen JC**, Borra R, Linderborg K, Kallio H, Kiss J, Lepomäki V, Kalliokoski KK, Kujala UM, Kaprio J, Heinonen OJ, Komu M, Parkkola R, Ahotupa M, Lehtimäki T, Huupponen R, Iozzo P, Nuutila P. Liver and pancreatic fat content and metabolism in healthy monozygotic twins with discordant physical activity. *J Hepatol* 2011; **54**: 545-552 [PMID: 21112658 DOI: 10.1016/j.jhep.2010.07.029]

62 **Heni M**, Machann J, Staiger H, Schwenzer NF, Peter A, Schick F, Claussen CD, Stefan N, Häring HU, Fritsche A. Pancreatic fat is negatively associated with insulin secretion in individuals with impaired fasting glucose and/or impaired glucose tolerance: a nuclear magnetic resonance study. *Diabetes Metab Res Rev* 2010; **26**: 200-205 [PMID: 20225188 DOI: 10.1002/dmrr.1073]

63 **Rebours V**, Garteiser P, Ribeiro-Parenti L, Cavin JB, Doblas S, Pagé G, Bado A, Couvineau A, Ruszniewski P, Paradis V, Le Gall M, Van Beers BE, Couvelard A. Obesity-induced pancreatopathy in rats is reversible after bariatric surgery. *Sci Rep* 2018; **8**: 16295 [PMID: 30390093 DOI: 10.1038/s41598-018-34515-3]

64 **Bray TJ**, Chouhan MD, Punwani S, Bainbridge A, Hall-Craggs MA. Fat fraction mapping using magnetic resonance imaging: insight into pathophysiology. *Br J Radiol* 2018; **91**: 20170344 [PMID: 28936896 DOI: 10.1259/bjr.20170344]

65 **Dixon WT**. Simple proton spectroscopic imaging. *Radiology* 1984; **153**: 189-194 [PMID: 6089263 DOI: 10.1148/radiology.153.1.6089263]

66 **Reeder SB**, Cruite I, Hamilton G, Sirlin CB. Quantitative Assessment of Liver Fat with Magnetic Resonance Imaging and Spectroscopy. *J Magn Reson Imaging* 2011; **34**: 729-749 [PMID: 22025886 DOI: 10.1002/jmri.22775]

67 **Yu H**, Shimakawa A, McKenzie CA, Brodsky E, Brittain JH, Reeder SB. Multiecho water-fat separation and simultaneous R2\* estimation with multifrequency fat spectrum modeling. *Magn Reson Med* 2008; **60**: 1122-1134 [PMID: 18956464 DOI: 10.1002/mrm.21737]

68 **Yokoo T**, Shiehmorteza M, Hamilton G, Wolfson T, Schroeder ME, Middleton MS, Bydder M, Gamst AC, Kono Y, Kuo A, Patton HM, Horgan S, Lavine JE, Schwimmer JB, Sirlin CB. Estimation of hepatic proton-density fat fraction by using MR imaging at 3.0 T. *Radiology* 2011; **258**: 749-759 [PMID: 21212366 DOI: 10.1148/radiol.10100659]

69 **Venkatesh SK**, Xu S, Tai D, Yu H, Wee A. Correlation of MR elastography with morphometric quantification of liver fibrosis (Fibro-C-Index) in chronic hepatitis B. *Magn Reson Med* 2014; **72**: 1123-1129 [PMID: 24166665 DOI: 10.1002/mrm.25002]

70 **Popescu A**, Săftoiu A. Can elastography replace fine needle aspiration? *Endosc Ultrasound* 2014; **3**: 109-117 [PMID: 24955340 DOI: 10.4103/2303-9027.123009]

71 **Siddiqui N**, Vendrami CL, Chatterjee A, Miller FH. Advanced MR Imaging Techniques for Pancreas Imaging. *Magn Reson Imaging Clin N Am* 2018; **26**: 323-344 [PMID: 30376973 DOI: 10.1016/j.mric.2018.03.002]

72 **An H**, Shi Y, Guo Q, Liu Y. Test-retest reliability of 3D EPI MR elastography of the pancreas. *Clin Radiol* 2016; **71**: 1068.e7-1068.e12 [PMID: 27132114 DOI: 10.1016/j.crad.2016.03.014]

73 **Hirooka Y**, Kuwahara T, Irisawa A, Itokawa F, Uchida H, Sasahira N, Kawada N, Itoh Y, Shiina T. JSUM ultrasound elastography practice guidelines: pancreas. *J Med Ultrason (2001)* 2015; **42**: 151-174 [PMID: 26576568 DOI: 10.1007/s10396-014-0571-7]

74 **Goertz RS**, Schuderer J, Strobel D, Pfeifer L, Neurath MF, Wildner D. Acoustic radiation force impulse shear wave elastography (ARFI) of acute and chronic pancreatitis and pancreatic tumor. *Eur J Radiol* 2016; **85**: 2211-2216 [PMID: 27842669 DOI: 10.1016/j.ejrad.2016.10.019]

75 **Sakai NS**, Taylor SA, Chouhan MD. Obesity, metabolic disease and the pancreas-Quantitative imaging of pancreatic fat. *Br J Radiol* 2018; **91**: 20180267 [PMID: 29869917 DOI: 10.1259/bjr.20180267]

76 **Dite P**, Blaho M, Bojkova M, Jabandziev P, Kunovsky L. Nonalcoholic Fatty Pancreas Disease: Clinical Consequences. *Dig Dis* 2020; **38**: 143-149 [PMID: 31865317 DOI: 10.1159/000505366]

77 **Elhady M**, Elazab AAAM, Bahagat KA, Abdallah NA, Ibrahim GE. Fatty pancreas in relation to insulin resistance and metabolic syndrome in children with obesity. *J Pediatr Endocrinol Metab* 2019; **32**: 19-26 [PMID: 30530906 DOI: 10.1515/jpem-2018-0315]

78 **Romana BS**, Chela H, Dailey FE, Nassir F, Tahan V. Non-Alcoholic Fatty Pancreas Disease (NAFPD): A Silent Spectator or the Fifth Component of Metabolic Syndrome? A Literature Review. *Endocr Metab Immune Disord Drug Targets* 2018; **18**: 547-554 [PMID: 29595117 DOI: 10.2174/1871530318666180328111302]

79 **Fraulob JC**, Ogg-Diamantino R, Fernandes-Santos C, Aguila MB, Mandarim-de-Lacerda CA. A Mouse Model of Metabolic Syndrome: Insulin Resistance, Fatty Liver and Non-Alcoholic Fatty Pancreas Disease (NAFPD) in C57BL/6 Mice Fed a High Fat Diet. *J Clin Biochem Nutr* 2010; **46**: 212-223 [PMID: 20490316 DOI: 10.3164/jcbn.09-83]

80 **Kaya SD**, Sinen O, Bülbül M. Gastric motor dysfunction coincides with the onset of obesity in rats fed with high-fat diet. *Clin Exp Pharmacol Physiol* 2021; **48**: 553-562 [PMID: 33352619 DOI: 10.1111/1440-1681.13448]

81 **Pavlov VA**. The evolving obesity challenge: targeting the vagus nerve and the inflammatory reflex in the response. *Pharmacol Ther* 2021; **222**: 107794 [PMID: 33310156 DOI: 10.1016/j.pharmthera.2020.107794]

82 **Chadda KR**, Cheng TS, Ong KK. GLP-1 agonists for obesity and type 2 diabetes in children: Systematic review and meta-analysis. *Obes Rev* 2021; **22**: e13177 [PMID: 33354917 DOI: 10.1111/obr.13177]

83 **Alberti KG**, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation* 2009; **120**: 1640-1645 [PMID: 19805654 DOI: 10.1161/CIRCULATIONAHA.109.192644]

84 **Kahn SE**, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. *Nature* 2006; **444**: 840-846 [PMID: 17167471 DOI: 10.1038/nature05482]

85 **Zhao ZZ**, Xin LL, Xia JH, Yang SL, Chen YX, Li K. Long-term High-fat High-sucrose Diet Promotes Enlarged Islets and β-Cell Damage by Oxidative Stress in Bama Minipigs. *Pancreas* 2015; **44**: 888-895 [PMID: 25906446 DOI: 10.1097/MPA.0000000000000349]

86 **van Raalte DH**, van der Zijl NJ, Diamant M. Pancreatic steatosis in humans: cause or marker of lipotoxicity? *Curr Opin Clin Nutr Metab Care* 2010; **13**: 478-485 [PMID: 20489606 DOI: 10.1097/MCO.0b013e32833aa1ef]

87 **Liu SN**, Liu Q, Lei L, Sun SJ, Li CN, Huan Y, Hou SC, Shen ZF. The Chinese patent medicine, Jin-tang-ning, ameliorates hyperglycemia through improving β cell function in pre-diabetic KKAy mice. *Chin J Nat Med* 2020; **18**: 827-836 [PMID: 33308603 DOI: 10.1016/S1875-5364(20)60023-1]

88 **Zhang X**, Cui Y, Fang L, Li F. Chronic high-fat diets induce oxide injuries and fibrogenesis of pancreatic cells in rats. *Pancreas* 2008; **37**: e31-e38 [PMID: 18815536 DOI: 10.1097/MPA.0b013e3181744b50]

89 **Steven S**, Hollingsworth KG, Small PK, Woodcock SA, Pucci A, Aribisala B, Al-Mrabeh A, Daly AK, Batterham RL, Taylor R. Weight Loss Decreases Excess Pancreatic Triacylglycerol Specifically in Type 2 Diabetes. *Diabetes Care* 2016; **39**: 158-165 [PMID: 26628414 DOI: 10.2337/dc15-0750]

90 **Tushuizen ME**, Bunck MC, Pouwels PJ, Bontemps S, van Waesberghe JH, Schindhelm RK, Mari A, Heine RJ, Diamant M. Pancreatic fat content and beta-cell function in men with and without type 2 diabetes. *Diabetes Care* 2007; **30**: 2916-2921 [PMID: 17666465 DOI: 10.2337/dc07-0326]

91 **Yamazaki H**, Tsuboya T, Katanuma A, Kodama Y, Tauchi S, Dohke M, Maguchi H. Lack of Independent Association Between Fatty Pancreas and Incidence of Type 2 Diabetes: 5-Year Japanese Cohort Study. *Diabetes Care* 2016; **39**: 1677-1683 [PMID: 27422578 DOI: 10.2337/dc16-0074]

92 **Boden G**. Free fatty acids-the link between obesity and insulin resistance. *Endocr Pract* 2001; **7**: 44-51 [PMID: 11250769 DOI: 10.4158/EP.7.1.44]

93 **van der Zijl NJ**, Goossens GH, Moors CC, van Raalte DH, Muskiet MH, Pouwels PJ, Blaak EE, Diamant M. Ectopic fat storage in the pancreas, liver, and abdominal fat depots: impact on β-cell function in individuals with impaired glucose metabolism. *J Clin Endocrinol Metab* 2011; **96**: 459-467 [PMID: 21084401 DOI: 10.1210/jc.2010-1722]

94 **Rossi AP**, Fantin F, Zamboni GA, Mazzali G, Rinaldi CA, Del Giglio M, Di Francesco V, Barillari M, Pozzi Mucelli R, Zamboni M. Predictors of ectopic fat accumulation in liver and pancreas in obese men and women. *Obesity (Silver Spring)* 2011; **19**: 1747-1754 [PMID: 21593811 DOI: 10.1038/oby.2011.114]

95 **Lê KA**, Ventura EE, Fisher JQ, Davis JN, Weigensberg MJ, Punyanitya M, Hu HH, Nayak KS, Goran MI. Ethnic differences in pancreatic fat accumulation and its relationship with other fat depots and inflammatory markers. *Diabetes Care* 2011; **34**: 485-490 [PMID: 21270204 DOI: 10.2337/dc10-0760]

96 **Della Corte C**, Mosca A, Majo F, Lucidi V, Panera N, Giglioni E, Monti L, Stronati L, Alisi A, Nobili V. Nonalcoholic fatty pancreas disease and Nonalcoholic fatty liver disease: more than ectopic fat. *Clin Endocrinol (Oxf)* 2015; **83**: 656-662 [PMID: 26201937 DOI: 10.1111/cen.12862]

97 **Pezzilli R**, Andriulli A, Bassi C, Balzano G, Cantore M, Delle Fave G, Falconi M; Exocrine Pancreatic Insufficiency collaborative (EPIc) Group. Exocrine pancreatic insufficiency in adults: a shared position statement of the Italian Association for the Study of the Pancreas. *World J Gastroenterol* 2013; **19**: 7930-7946 [PMID: 24307787 DOI: 10.3748/wjg.v19.i44.7930]

98 **Dupont C**, Sellier N, Chochillon C, Gobert JG, Helardot PG, Kalifa G. Pancreatic lipomatosis and duodenal stenosis or atresia in children. *J Pediatr* 1989; **115**: 603-605 [PMID: 2795357 DOI: 10.1016/s0022-3476(89)80293-8]

99 **Patel S**, Bellon EM, Haaga J, Park CH. Fat replacement of the exocrine pancreas. *AJR Am J Roentgenol* 1980; **135**: 843-845 [PMID: 6778124 DOI: 10.2214/ajr.135.4.843]

100 **Lozano M**, Navarro S, Pérez-Ayuso R, Llach J, Ayuso C, Guevara MC, Ros E. Lipomatosis of the pancreas: an unusual cause of massive steatorrhea. *Pancreas* 1988; **3**: 580-582 [PMID: 3186686 DOI: 10.1097/00006676-198810000-00012]

101 **Hellara O**, Saad J, Ben Chaabene N, Ben Mansour W, Melki W, Loghmari H, Bdioui F, Safer L, Saffar H. [Diffuse primary fat replacement of the pancreas: an unusual cause of steatorrhea]. *Tunis Med* 2013; **91**: 359-360 [PMID: 23716335]

102 **Ambesh P**, Lal H. Pancreatic Lipomatosis: Complete Replacement of Pancreas by Fat. *J Clin Diagn Res* 2015; **9**: OL01 [PMID: 26557560 DOI: 10.7860/JCDR/2015/15085.6653]

103 **Tahtacı M**, Algın O, Karakan T, Yürekli ÖT, Alışık M, Köseoğlu H, Metin MR, Bolat AD, Erel Ö, Ersoy O. Can pancreatic steatosis affect exocrine functions of pancreas? *Turk J Gastroenterol* 2018; **29**: 588-594 [PMID: 30260782 DOI: 10.5152/tjg.2018.17696]

104 **Midiri M**, Lo Casto A, Sparacia G, D'Angelo P, Malizia R, Finazzo M, Montalto G, Solbiati L, Lagalla R, De Maria M. MR imaging of pancreatic changes in patients with transfusion-dependent beta-thalassemia major. *AJR Am J Roentgenol* 1999; **173**: 187-192 [PMID: 10397124 DOI: 10.2214/ajr.173.1.10397124]

105 **So CB**, Cooperberg PL, Gibney RG, Bogoch A. Sonographic findings in pancreatic lipomatosis. *AJR Am J Roentgenol* 1987; **149**: 67-68 [PMID: 3296712 DOI: 10.2214/ajr.149.1.67]

106 **Melitas C**, Meiselman M. Metabolic Pancreatitis: Pancreatic Steatosis, Hypertriglyceridemia, and Associated Chronic Pancreatitis in 3 Patients with Metabolic Syndrome. *Case Rep Gastroenterol* 2018; **12**: 331-336 [PMID: 30022925 DOI: 10.1159/000490042]

107 **Cnop M**, Hannaert JC, Hoorens A, Eizirik DL, Pipeleers DG. Inverse relationship between cytotoxicity of free fatty acids in pancreatic islet cells and cellular triglyceride accumulation. *Diabetes* 2001; **50**: 1771-1777 [PMID: 11473037 DOI: 10.2337/diabetes.50.8.1771]

108 **Martínez J**, Sánchez-Payá J, Palazón JM, Suazo-Barahona J, Robles-Díaz G, Pérez-Mateo M. Is obesity a risk factor in acute pancreatitis? A meta-analysis. *Pancreatology* 2004; **4**: 42-48 [PMID: 14988657 DOI: 10.1159/000077025]

109 **Martínez J**, Johnson CD, Sánchez-Payá J, de Madaria E, Robles-Díaz G, Pérez-Mateo M. Obesity is a definitive risk factor of severity and mortality in acute pancreatitis: an updated meta-analysis. *Pancreatology* 2006; **6**: 206-209 [PMID: 16549939 DOI: 10.1159/000092104]

110 **Acharya C**, Navina S, Singh VP. Role of pancreatic fat in the outcomes of pancreatitis. *Pancreatology* 2014; **14**: 403-408 [PMID: 25278311 DOI: 10.1016/j.pan.2014.06.004]

111 **Zyromski NJ**, Mathur A, Pitt HA, Lu D, Gripe JT, Walker JJ, Yancey K, Wade TE, Swartz-Basile DA. A murine model of obesity implicates the adipokine milieu in the pathogenesis of severe acute pancreatitis. *Am J Physiol Gastrointest Liver Physiol* 2008; **295**: G552-G558 [PMID: 18583460 DOI: 10.1152/ajpgi.90278.2008]

112 **Lankisch PG**, Schirren CA. Increased body weight as a prognostic parameter for complications in the course of acute pancreatitis. *Pancreas* 1990; **5**: 626-629 [PMID: 2235973 DOI: 10.1097/00006676-199009000-00021]

113 **Suazo-Baráhona J**, Carmona-Sánchez R, Robles-Díaz G, Milke-García P, Vargas-Vorácková F, Uscanga-Domínguez L, Peláez-Luna M. Obesity: a risk factor for severe acute biliary and alcoholic pancreatitis. *Am J Gastroenterol* 1998; **93**: 1324-1328 [PMID: 9707059 DOI: 10.1111/j.1572-0241.1998.442\_l.x]

114 **Blomgren KB**, Sundström A, Steineck G, Wiholm BE. Obesity and treatment of diabetes with glyburide may both be risk factors for acute pancreatitis. *Diabetes Care* 2002; **25**: 298-302 [PMID: 11815499 DOI: 10.2337/diacare.25.2.298]

115 **Funnell IC**, Bornman PC, Weakley SP, Terblanche J, Marks IN. Obesity: an important prognostic factor in acute pancreatitis. *Br J Surg* 1993; **80**: 484-486 [PMID: 8495317 DOI: 10.1002/bjs.1800800426]

116 **Frossard JL**, Lescuyer P, Pastor CM. Experimental evidence of obesity as a risk factor for severe acute pancreatitis. *World J Gastroenterol* 2009; **15**: 5260-5265 [PMID: 19908332 DOI: 10.3748/wjg.15.5260]

117 **Ronti T**, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update. *Clin Endocrinol (Oxf)* 2006; **64**: 355-365 [PMID: 16584505 DOI: 10.1111/j.1365-2265.2006.02474.x]

118 **Shoelson SE**, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. *Gastroenterology* 2007; **132**: 2169-2180 [PMID: 17498510 DOI: 10.1053/j.gastro.2007.03.059]

119 **de Oliveira C**, Khatua B, Noel P, Kostenko S, Bag A, Balakrishnan B, Patel KS, Guerra AA, Martinez MN, Trivedi S, McCullough A, Lam-Himlin DM, Navina S, Faigel DO, Fukami N, Pannala R, Phillips AE, Papachristou GI, Kershaw EE, Lowe ME, Singh VP. Pancreatic triglyceride lipase mediates lipotoxic systemic inflammation. *J Clin Invest* 2020; **130**: 1931-1947 [PMID: 31917686 DOI: 10.1172/JCI132767]

120 **Mathur A**, Marine M, Lu D, Swartz-Basile DA, Saxena R, Zyromski NJ, Pitt HA. Nonalcoholic fatty pancreas disease. *HPB (Oxford)* 2007; **9**: 312-318 [PMID: 18345311 DOI: 10.1080/13651820701504157]

121 **Pitt HA**. Hepato-pancreato-biliary fat: the good, the bad and the ugly. *HPB (Oxford)* 2007; **9**: 92-97 [PMID: 18333122 DOI: 10.1080/13651820701286177]

122 **Yang DM**, Kim HC, Ryu JK, Joo KR, Ahn KJ. Sonographic appearance of focal fatty infiltration of the pancreas. *J Clin Ultrasound* 2010; **38**: 45-47 [PMID: 19790258 DOI: 10.1002/jcu.20632]

123 **Gaujoux S**, Cortes A, Couvelard A, Noullet S, Clavel L, Rebours V, Lévy P, Sauvanet A, Ruszniewski P, Belghiti J. Fatty pancreas and increased body mass index are risk factors of pancreatic fistula after pancreaticoduodenectomy. *Surgery* 2010; **148**: 15-23 [PMID: 20138325 DOI: 10.1016/j.surg.2009.12.005]

124 **Lee SE**, Jang JY, Lim CS, Kang MJ, Kim SH, Kim MA, Kim SW. Measurement of pancreatic fat by magnetic resonance imaging: predicting the occurrence of pancreatic fistula after pancreatoduodenectomy. *Ann Surg* 2010; **251**: 932-936 [PMID: 20395858 DOI: 10.1097/SLA.0b013e3181d65483]

125 **Tranchart H**, Gaujoux S, Rebours V, Vullierme MP, Dokmak S, Levy P, Couvelard A, Belghiti J, Sauvanet A. Preoperative CT scan helps to predict the occurrence of severe pancreatic fistula after pancreaticoduodenectomy. *Ann Surg* 2012; **256**: 139-145 [PMID: 22609844 DOI: 10.1097/SLA.0b013e318256c32c]

126 **Søreide K**, Labori KJ. Risk factors and preventive strategies for post-operative pancreatic fistula after pancreatic surgery: a comprehensive review. *Scand J Gastroenterol* 2016; **51**: 1147-1154 [PMID: 27216233 DOI: 10.3109/00365521.2016.1169317]

127 **Honka H**, Koffert J, Hannukainen JC, Tuulari JJ, Karlsson HK, Immonen H, Oikonen V, Tolvanen T, Soinio M, Salminen P, Kudomi N, Mari A, Iozzo P, Nuutila P. The effects of bariatric surgery on pancreatic lipid metabolism and blood flow. *J Clin Endocrinol Metab* 2015; **100**: 2015-2023 [PMID: 25734253 DOI: 10.1210/jc.2014-4236]

128 **Karasu S**, Gungor F, Onak C, Dilek ON. Relation of computed tomography features of the pancreatic tissue and development of pancreatic fistula after pancreaticoduodenectomy. *Clin Imaging* 2021; **72**: 114-119 [PMID: 33227614 DOI: 10.1016/j.clinimag.2020.10.034]

129 **Guo XJ**, Zhu F, Yang MW, Jiang JX, He Z, Gao J, Huang T, Zhao R, Zhang LD, Wang M, Qin RY; FACS. A score model based on pancreatic steatosis and fibrosis and pancreatic duct diameter to predict postoperative pancreatic fistula after Pancreatoduodenectomy. *BMC Surg* 2019; **19**: 75 [PMID: 31269932 DOI: 10.1186/s12893-019-0534-4]

130 **Huang J**, Lok V, Ngai CH, Zhang L, Yuan J, Lao XQ, Ng K, Chong C, Zheng ZJ, Wong MCS. Worldwide Burden of, Risk Factors for, and Trends in Pancreatic Cancer. *Gastroenterology* 2021; **160**: 744-754 [PMID: 33058868 DOI: 10.1053/j.gastro.2020.10.007]

131 **Téoule P**, Rasbach E, Oweira H, Otto M, Rahbari NN, Reissfelder C, Rückert F, Birgin E. Obesity and Pancreatic Cancer: A Matched-Pair Survival Analysis. *J Clin Med* 2020; **9** [PMID: 33142763 DOI: 10.3390/jcm9113526]

132 **Chung HS**, Lee JS, Song E, Kim JA, Roh E, Yu JH, Kim NH, Yoo HJ, Seo JA, Kim SG, Kim NH, Baik SH, Choi KM. Effect of Metabolic Health and Obesity Phenotype on the Risk of Pancreatic Cancer: A Nationwide Population-Based Cohort Study. *Cancer Epidemiol Biomarkers Prev* 2021; **30**: 521-528 [PMID: 33277320 DOI: 10.1158/1055-9965.EPI-20-1262]

133 **Lang J**, Kunovský L, Kala Z, Trna J. Risk factors of pancreatic cancer and their possible uses in diagnostics. *Neoplasma* 2021; **68**: 227-239 [PMID: 33350848 DOI: 10.4149/neo\_2020\_200706N699]

134 **Patel AV**, Rodriguez C, Bernstein L, Chao A, Thun MJ, Calle EE. Obesity, recreational physical activity, and risk of pancreatic cancer in a large U.S. Cohort. *Cancer Epidemiol Biomarkers Prev* 2005; **14**: 459-466 [PMID: 15734973 DOI: 10.1158/1055-9965.EPI-04-0583]

135 **Lesmana CRA**, Gani RA, Lesmana LA. Non-alcoholic fatty pancreas disease as a risk factor for pancreatic cancer based on endoscopic ultrasound examination among pancreatic cancer patients: A single-center experience. *JGH Open* 2018; **2**: 4-7 [PMID: 30483555 DOI: 10.1002/jgh3.12032]

136 **Hori M**, Takahashi M, Hiraoka N, Yamaji T, Mutoh M, Ishigamori R, Furuta K, Okusaka T, Shimada K, Kosuge T, Kanai Y, Nakagama H. Association of pancreatic Fatty infiltration with pancreatic ductal adenocarcinoma. *Clin Transl Gastroenterol* 2014; **5**: e53 [PMID: 24622469 DOI: 10.1038/ctg.2014.5]

137 **Rebours V**, Gaujoux S, d'Assignies G, Sauvanet A, Ruszniewski P, Lévy P, Paradis V, Bedossa P, Couvelard A. Obesity and Fatty Pancreatic Infiltration Are Risk Factors for Pancreatic Precancerous Lesions (PanIN). *Clin Cancer Res* 2015; **21**: 3522-3528 [PMID: 25700304 DOI: 10.1158/1078-0432.CCR-14-2385]

138 **Mathur A**, Hernandez J, Shaheen F, Shroff M, Dahal S, Morton C, Farrior T, Kedar R, Rosemurgy A. Preoperative computed tomography measurements of pancreatic steatosis and visceral fat: prognostic markers for dissemination and lethality of pancreatic adenocarcinoma. *HPB (Oxford)* 2011; **13**: 404-410 [PMID: 21609373 DOI: 10.1111/j.1477-2574.2011.00304.x]

139 **Prachayakul V**, Aswakul P. Pancreatic Steatosis: What Should Gastroenterologists Know? *JOP* 2015; **16**: 227-231

140 **Mathur A**, Zyromski NJ, Pitt HA, Al-Azzawi H, Walker JJ, Saxena R, Lillemoe KD. Pancreatic steatosis promotes dissemination and lethality of pancreatic cancer. *J Am Coll Surg* 2009; **208**: 989-94; discussion 994-6 [PMID: 19476877 DOI: 10.1016/j.jamcollsurg.2008.12.026]

141 **Annett S**, Moore G, Robson T. Obesity and Cancer Metastasis: Molecular and Translational Perspectives. *Cancers (Basel)* 2020; **12** [PMID: 33339340 DOI: 10.3390/cancers12123798]

142 **Lammert E**, Cleaver O, Melton D. Role of endothelial cells in early pancreas and liver development. *Mech Dev* 2003; **120**: 59-64 [PMID: 12490296 DOI: 10.1016/s0925-4773(02)00332-5]

143 **Donnelly KL**, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted *via* lipoproteins in patients with nonalcoholic fatty liver disease. *J Clin Invest* 2005; **115**: 1343-1351 [PMID: 15864352 DOI: 10.1172/JCI23621]

144 **Yamazaki H**, Tauchi S, Kimachi M, Dohke M, Hanawa N, Kodama Y, Katanuma A, Yamamoto Y, Fukuma S, Fukuhara S. Association between pancreatic fat and incidence of metabolic syndrome: a 5-year Japanese cohort study. *J Gastroenterol Hepatol* 2018; **33**: 2048-2054 [PMID: 29697157 DOI: 10.1111/jgh.14266]

145 **Chalasani N**, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. *Hepatology* 2018; **67**: 328-357 [PMID: 28714183 DOI: 10.1002/hep.29367]

146 **Zhou J**, Li ML, Zhang DD, Lin HY, Dai XH, Sun XL, Li JT, Song LY, Peng H, Wen MM. The correlation between pancreatic steatosis and metabolic syndrome in a Chinese population. *Pancreatology* 2016; **16**: 578-583 [PMID: 27050733 DOI: 10.1016/j.pan.2016.03.008]

147 **Dreiling DA**, Elsbach P, Schaffner F, Schwartz IL. The effect of restriction of protein and total calories on pancreatic function in obese patients. *Gastroenterology* 1962; **42**: 686-690 [PMID: 13887768]

148 **Jia DM**, Fukumitsu KI, Tabaru A, Akiyama T, Otsuki M. Troglitazone stimulates pancreatic growth in congenitally CCK-A receptor-deficient OLETF rats. *Am J Physiol Regul Integr Comp Physiol* 2001; **280**: R1332-R1340 [PMID: 11294751 DOI: 10.1152/ajpregu.2001.280.5.R1332]

149 **Patel K**, Trivedi RN, Durgampudi C, Noel P, Cline RA, DeLany JP, Navina S, Singh VP. Lipolysis of visceral adipocyte triglyceride by pancreatic lipases converts mild acute pancreatitis to severe pancreatitis independent of necrosis and inflammation. *Am J Pathol* 2015; **185**: 808-819 [PMID: 25579844 DOI: 10.1016/j.ajpath.2014.11.019]

150 **Zsóri G**, Illés D, Ivány E, Kosár K, Holzinger G, Tajti M, Pálinkás E, Szabovik G, Nagy A, Palkó A, Czakó L. In New-Onset Diabetes Mellitus, Metformin Reduces Fat Accumulation in the Liver, But Not in the Pancreas or Pericardium. *Metab Syndr Relat Disord* 2019; **17**: 289-295 [PMID: 31013454 DOI: 10.1089/met.2018.0086]

151 **Fang T**, Huang S, Chen Y, Chen Z, Chen J, Hu W. Glucagon Like Peptide-1 Receptor Agonists Alters Pancreatic and Hepatic Histology and Regulation of Endoplasmic Reticulum Stress in High-fat Diet Mouse Model. *Exp Clin Endocrinol Diabetes* 2020 [PMID: 32961563 DOI: 10.1055/a-1240-4936]

152 **Souza-Mello V**, Gregório BM, Relvas-Lucas B, da Silva Faria T, Aguila MB, Mandarim-de-Lacerda CA. Pancreatic ultrastructural enhancement due to telmisartan plus sitagliptin treatment in diet-induced obese C57BL/6 mice. *Pancreas* 2011; **40**: 715-722 [PMID: 21602737 DOI: 10.1097/MPA.0b013e3182153922]

153 **Zhao L**, Jiang SJ, Lu FE, Xu LJ, Zou X, Wang KF, Dong H. Effects of berberine and cinnamic acid on palmitic acid-induced intracellular triglyceride accumulation in NIT-1 pancreatic β cells. *Chin J Integr Med* 2016; **22**: 496-502 [PMID: 25491540 DOI: 10.1007/s11655-014-1986-0]

**Footnotes**

**Conflict-of-interest statement:** No potential conflicts of interest relevant to this article were reported.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** March 11, 2021

**First decision:** May 12, 2021

**Article in press:**

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Catanzaro R, Patoulias DI **S-Editor:** Gao CC **L-Editor:** Filipodia **P-Editor:**

**Table 1 Nomenclature of the fat in the pancreas**

|  |  |
| --- | --- |
| Name | Definition |
| Pancreatic steatosis; Pancreatic lipomatosis; Fatty pancreas | General terms for pancreatic fat accumulation |
| Fatty replacement | Death of acinar cells — replacement with adipocytes |
| Fatty infiltration | Infiltration with adipocytes due to obesity |
| NAFPD | Pancreatic fat accumulation + obesity and metabolic syndrome |
| NASP | Pancreatitis due to pancreatic fat accumulation |

NAFPD: Nonalcoholic fatty pancreas disease; NASP: nonalcoholic steatopancreatitis.